Characterization of Elderly Patients (≥70 Years) with Neuroendocrine Tumors (NETs) Abstract #710

Introduction: Incidence of NETs increases with age; however, age-specific epidemiologic analyses are lacking.
Aim(s): To epidemiologically characterize elderly patients (pts) with NETs and their association with NET prognostic factors.
Materials and methods: The data from the Spanish Regional ATNEA Registry were analysed for differences between the older (≥70 y) and younger (<70 y) patient population.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: María Isabel Sevilla García
Keywords: elderly, NETs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Ivana Puliafito
#1908 Staging Classification Comparison of Resected Pancreatic Neuroendocrine Tumors (pNETs) Utilizing the National Cancer Database (NCDB)
Introduction: The staging classification of pNETs remains a matter of debate and no obvious superior system has emerged.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Gustavo Westin
#445 Comparison of Prognostic Capacity for Overall Survival (OS) and Disease-Free Survival (DFS) of Neuroendocrine Tumors (NETs) Classifications: 2010 WHO, TNM Staging-ENETS and AJCC
Introduction: Current NETs classifications are: WHO, ENETS and AJCC. No consensus exists about which one more accurately predicts NET outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dra Nuria Mulet-Margalef
#554 Analysis of the AJCC/ENETS Staging Classification for Midgut Neuroendocrine Tumors
Introduction: The American Joint Committee on Cancer (AJCC) and ENETS have independently introduced a novel TNM staging classification for jejunal-ileal NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Max Feldman
#214 Comparison of the AJCC and ENETS Staging Classifications for Neuroendocrine Tumors of the Pancreas
Introduction: The AJCC Cancer Staging Manual (7th edition, 2010) has introduced a novel TNM staging classification for pancreatic NETs. This classification has not yet been validated.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Cheema A, Weber J, Kvols L, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.